JAZZ vs. NBIX: Jazz Pharmaceuticals vs. Neurocrine Biosciences Stock Comparison

Company Profile

Jazz Pharmaceuticals (JAZZ) and Neurocrine Biosciences (NBIX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JAZZ is classified in Pharmaceuticals while NBIX is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Neurocrine Biosciences (NBIX) at 20.42% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for NBIX.

Neurocrine Biosciences (NBIX) at 18.98% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.

Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Neurocrine Biosciences (NBIX) at 31.98% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Neurocrine Biosciences (NBIX) at 21.45% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Neurocrine Biosciences (NBIX) at 41.95% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Neurocrine Biosciences (NBIX) at 2.04 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Neurocrine Biosciences (NBIX) at 0.12 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Jazz Pharmaceuticals (JAZZ) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Jazz Pharmaceuticals (JAZZ) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neurocrine Biosciences (NBIX) at 24.43 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Neurocrine Biosciences (NBIX) at 4.50 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Jazz Pharmaceuticals (JAZZ) at 3.59 and Neurocrine Biosciences (NBIX) at 4.30 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics